Celera Genomics Rockville Company Profile
Celera is a molecular diagnostics business with powerful discovery platforms dedicated to the practice of Targeted Medicine. Located in Rockville, MD and Alameda, CA, the company employs about 300 people and has the full capability to discover, develop, manufacture and secure registration for In Vitro Diagnostic products. To identify novel diagnostic markers and potential drug targets, we are leveraging capabilities in proteomics, genomics and bioinformatics to better understand the association between common diseases (cardiovascular, autoimmune and cancer) and patterns of genetic variation and protein expression. Our strategy is to be a leader in Targeted Medicine by producing new genetic and proteomic-based diagnostics tests that improve patient outcome by predicting disease risk, selecting the most effective therapy and monitoring treatment. Another goal is to capitalize on the value of our discoveries through partnerships to develop new therapies, identify new disease indications for existing drugs, and to provide pharmacogenomic and companion diagnostic tests.Celera has a strategic alliance with Abbott Laboratories through which the companies sell and support molecular diagnostic products. Celera's discovery platforms are the basis for multiple discovery and therapeutic product development collaborations.
Location
45 West Gude Drive
Rockville
Maryland
20850
United States of America
Contact
Phone: (240) 453-3000
Email: investorinfo@celera.com
News Articles
New algorithm for faster human genome sequencing
In 2001, the Human Genome Project and Celera Genomics announced that after 10 years of work at a cost of some $400 million, they had completed a draft sequence of the human genome. Today, sequencing a...
Genomics center gets $1.8M to study livestock
The Roslin Institute's ARK-Genomics Centre for Comparative and Functional Genomics received a $1.8 million boost from the U.K -More-
Ready or Not, Genomics is Coming to a Hospital Near You
First came genomics for scientists. Then came genomics for Big Pharma. But this year, at a faster pace than many industry insiders anticipated, we’re seeing genomics enter the world of real-life car...
Complete Genomics snubs Illumina bid
Complete Genomics Inc. (NASDAQ:GNOM) disclosed in an SEC filing that its board unanimously deemed as "inadequate" an unsolicited bid from fellow sequencing company Illumina Inc. (NASDAQ:ILMN) to acqui...
BioNano Genomics launches Irys for complex human genome analysis
BioNano Genomics, a San Diego-based genomics company, has launched its Irys System, an intuitively designed genome mapping system that empowers genomics researchers with a new way of analyzing genomic...
In 2001, the Human Genome Project and Celera Genomics announced that after 10 years of work at a cost of some $400 million, they had completed a draft sequence of the human genome. Today, sequencing a...
Ebb & Flow Completing genomics Neither Complete Genomics Inc. (NASDAQ:GNOM) nor its investors are talking about the bargain-basement takeout by Chinese genomics company BGI, but what is clear is the s...
BGI to acquire Complete Genomics
BGI (Shenzhen, China) will acquire whole genome sequencing company Complete Genomics Inc. (NASDAQ:GNOM) for $3.15 per share in cash, or about $117.6 million. The price is an 18% premium to Complete Ge...
Drugs and Medications
Oxygen-nitrogen mixture [Roberts Oxygen Company, Inc.]
Oxygen-Nitrogen Mixture
Oxygen-nitrogen mixture [Roberts Oxygen Company, Inc.]
Oxygen-Nitrogen Mixture
Oxygen-nitrogen mixture [Roberts Oxygen Company, Inc.]
Oxygen-Nitrogen Mixture
Oxygen-nitrogen mixture [Roberts Oxygen Company, Inc.]
Oxygen-Nitrogen Mixture
Oxygen-nitrogen mixture [Roberts Oxygen Company, Inc.]
Oxygen-Nitrogen Mixture
PubMed Articles
The success of structural genomics.
The International Conference on Structural Genomics (ICSG 2011, http://www.icsg2011.org ), held in Toronto Canada May 10-14, 2011 was a rich and exciting demonstration of how far structural genomics h...
Personal Genomics: are we debating the right Issues?.
The debate about personal genomics and their role in personalized medicine has been, to some extent, hijacked by the controversy about commercially available genomic tests sold directly to consumers....
The human reference genome is still incomplete and a number of gene sequences are missing from it. The approaches to uncover them, the reasons causing their absence and their functions are less explor...
Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2009.
Draft genome sequence of the oilseed species Ricinus communis.
Castor bean (Ricinus communis) is an oilseed crop that belongs to the spurge (Euphorbiaceae) family, which comprises approximately 6,300 species that include cassava (Manihot esculenta), rubber tree (...
Clinical Trials
Genomics and Postoperative Atrial Fibrillation
This research study is done to find out if genetic make up of a person plays a role in complications and recovery after the Coronary Artery Bypass Graft (CABG) operation. As you may be aw...
Inflammatory Genomics in Human Carotid Artery Disease
To investigate the relationship between genetic variation in genes for inflammation and carotid artery atherosclerosis.
A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.
Dopamine (DA) plays a critical role in nicotine (and other) addiction and this drug is known to release DA in brain areas mediating reward and motivational processes. Although imaging stud...
Genomics, Single Nucleotide Polymorphisms (SNPs), and Clinical Neonatology
This research seeks to establish a neonatal DNA Tissue Bank to find out if differences in small segments of DNA predispose babies to Chronic Lung Disease (CLD), Periventricular Brain Injur...
Risk Factors and Molecular Genomics of U.S. Patients With Chronic Liver Disease &Hepatocellular CA
To identify risk factors for the development and diagnosis of hepatocellular CA in patients with chronic hepatitis C and to use the data to ultimately develop an effective screening progra...
Companies
PE Corporation-Celera Genomics
The Celera Genomics Group is engaged principally in integrating advanced technologies to create therapeutic discovery and development capabilities for internal use and for its customers and collaborat...
Celera is engaged principally in integrating high throughput technologies to create therapeutic discovery and development capabilities for internal use and for its customers and collaborators. Celera...
Celera is a molecular diagnostics business with powerful discovery platforms dedicated to the practice of Targeted Medicine. Located in Rockville, MD and Alameda, CA, the company employs about 300 peo...
Celera is a healthcare business focusing on the integration of genetic testing into routine clinical care through a combination of products and services incorporating proprietary...
Genomics One is a fully integrated biotechnology company committed to the creation of shareholder value through innovation in the fields of genomics, proteomics and mono-clonal antibodies. The mission...
More Information about "Celera Genomics Rockville" on BioPortfolio
We have published hundreds of Celera Genomics Rockville news stories on BioPortfolio along with dozens of Celera Genomics Rockville Clinical Trials and PubMed Articles about Celera Genomics Rockville for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Celera Genomics Rockville Companies in our database. You can also find out about relevant Celera Genomics Rockville Drugs and Medications on this site too.
